bioMerieux (FR:BIM) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
bioMérieux has announced FDA 510(k) clearance for its VITEK® REVEAL™ antibiogram system, which provides rapid antibiotic sensitivity tests crucial for treating sepsis and combating antibiotic resistance. This innovative technology delivers results from positive blood cultures within approximately 5.5 to 6 hours, enabling same-day therapeutic decisions. The clearance marks a significant milestone for bioMérieux, enhancing its comprehensive solutions in the diagnostics market and supporting the proper use of antibiotics.
For further insights into FR:BIM stock, check out TipRanks’ Stock Analysis page.